Zentalis Pharmaceuticals, Inc. Stock Price, News & Analysis

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Anthony Sun will present at the Oppenheimer Annual Healthcare Conference on March 16, 2022, at 10:00 a.m. ET. The presentation will be accessible via a live webcast on the company’s website, with an archived version available afterward. Zentalis focuses on developing small molecule therapeutics for cancer treatment, with a promising pipeline including ZN-c3 (Wee1 inhibitor), ZN-c5 (SERD), and ZN-d5 (BCL-2 inhibitor). The company operates from New York and San Diego.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) will present updated data from the Phase 1 expansion cohort of its Wee1 inhibitor ZN-c3 for uterine serous carcinoma (USC) at the AACR Annual Meeting 2022, scheduled for April 8-13 in New Orleans. The company highlights five accepted abstracts, including a mini symposium detailing ZN-c3's efficacy and safety. CEO Dr. Anthony Sun expressed optimism about the ongoing trials, noting ZN-c3's promising durability and tolerability. The company aims to explore ZN-c3's potential in combination therapies.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) received Fast Track designation from the FDA for its Wee1 Inhibitor, ZN-c3, targeting uterine serous carcinoma. The company has launched two new trials for ZN-c3 and added a preclinical BCL-xL heterobifunctional degrader candidate to its pipeline. As of December 31, 2021, Zentalis reported $339.9 million in cash and equivalents, which is expected to fund operations into Q3 2023. R&D expenses rose to $175.6 million, indicating intensified clinical pipeline advancements.

Zentalis Pharmaceuticals (Nasdaq: ZNTL), a biopharmaceutical firm, announced CEO Anthony Sun's participation in virtual investor conferences. The events include the Guggenheim Oncology Conference on February 10, 2022, at 10:30 a.m. EST, and the SVB Leerink 2022 Global Healthcare Conference on February 17, 2022, at 1:00 p.m. EST. Webcasts will be available on Zentalis's website post-event. The company focuses on developing innovative cancer therapies, including ZN-c3, ZN-c5, ZN-d5, and ZN-e4, targeting various cancer types.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) is hosting a virtual R&D Day on December 16, 2021, from 11:00 a.m. to 12:00 p.m. EST. The event will feature management and three Key Opinion Leaders discussing preclinical science and clinical updates on pipeline candidates, including ZN-d5, an oral BCL-2 inhibitor, and ZN-e4, an oral EGFR inhibitor. Registration is available on their website. Zentalis specializes in developing small molecule therapeutics targeting cancer-related biological pathways.

Zentalis Pharmaceuticals announces the FDA has granted Fast Track designation for its oral WEE1 inhibitor candidate, ZN-c3, aimed at treating recurrent uterine serous carcinoma (USC). This development is significant due to the aggressive nature of USC and its high recurrence rates, underscoring the urgent need for effective therapies. ZN-c3 is currently in a potential registrational Phase 2 trial, with safety updates expected in the second half of 2022. Fast Track designation allows for streamlined communication with the FDA, potentially expediting the approval process.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported financial results for Q3 2021, revealing a net loss of $10.5 million, significantly lower than the $34.7 million loss in Q3 2020. The company initiated a Phase 1/2 trial for ZN-c3 combined with gemcitabine in osteosarcoma and is progressing in a Phase 2 trial for uterine serous carcinoma. As of September 30, 2021, Zentalis holds $366.8 million in cash, expected to sustain operations through Q3 2023. Research and development expenses increased to $54 million, reflecting enhanced clinical activities.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has announced that CEO Anthony Sun will present at two upcoming investor conferences. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 17, 2021, at 8:40 a.m. EST, while the Jefferies London Healthcare Conference will be available on-demand starting November 18, 2021, at 8:00 a.m. GMT. Webcasts for these presentations will be accessible via the company’s website. Zentalis focuses on developing small molecule therapeutics for cancer treatment.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has initiated a Phase 1/2 trial for ZN-c3, an oral WEE1 inhibitor, in combination with gemcitabine for treating relapsed or refractory osteosarcoma. The trial aims to evaluate clinical safety and efficacy, with initial results expected in the second half of 2022. Zentalis has received orphan drug and rare pediatric disease designations from the FDA for this indication, potentially leading to a priority voucher upon approval. Osteosarcoma, primarily affecting younger patients, has a poor prognosis, highlighting the urgent need for effective therapies.